Code Bio: Code Biotherapeutics Raises $75 Million in Series A Financing

Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-viral delivery of genetic medicines, raised $75M in Series A funding. The round was led by Northpond Ventures with participation from Amgen Ventures, Hatteras Venture Partners, UCB Ventures, New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. As part [...]The post Code Biotherapeutics Raises $75 Million in Series A Financing appeared first on FinSMEs.